:strip_icc()/i.s3.glbimg.com/v1/AUTH_e536e40f1baf4c1a8bf1ed12d20577fd/internal_photos/bs/2022/5/W/Xh3OuVQVuP9Z6AWqsrPQ/pexels-martin-lopez-954583.jpg "Johnson & Johnson cancels HIV vaccine trials | Science and health")
Johnson & Johnson waives its HIV vaccine which was being tested, according to the news agency Reuters. The vaccine, which was already in phase 3 testing, was found to be ineffective in preventing viral infections.
Last year, preliminary news already indicated that the efforts of the pharmaceutical company were not yielding the expected results. This is therefore bad news for the expectations of fighting a virus known to mutate rapidly and evade all defensive responses tested.
+ The scientist who smuggled HIV into her country in her bag to study it and save lives
+ Fight against HIV: why the drop in infections is the worst since 2016
“Developing a safe and effective HIV vaccine has been a significant scientific challenge, but we will learn from this study and move forward,” said a spokesperson for the US National Institute of Allergy and Infectious Diseases. , Johnson & Johnson’s testing partner. , told Reuters.
The J&J study, which began in 2019, was conducted in 50 locations around the world with 3,900 people.
According to the World Health Organization, in 2021, 650,000 people died from causes related to HIV infection worldwide and 1.5 million people contracted the virus.
Another HIV vaccine trial, conducted by researchers from several North American institutions, showed encouraging results in an experimental study. However, this is a test still in phase 1.
“Typical thinker. Unapologetic alcoholaholic. Internet fanatic. Pop culture advocate. Tv junkie.”
:strip_icc()/i.s3.glbimg.com/v1/AUTH_da025474c0c44edd99332dddb09cabe8/internal_photos/bs/2023/D/n/i7eIkcQsAB0YgsWKDQMw/whatsapp-image-2023-03-08-at-10.48.49.jpeg)
:strip_icc()/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2021/T/V/IFkavRRSSjHCBPZfqVXw/ap21313490536644.jpg)